Raising a heterologous tier 2 neutralizing antibody (nAb) response stays a daunting job for HIV vaccine growth. In this research, we explored the utility of numerous HIV-1 envelope (Env) immunogens in a sequential immunization scheme as a answer to this job. This exploration stemmed from the rationale that gp145, a membrane-bound truncation kind of HIV Env, could facilitate the focusing of induced antibody response on neutralizing epitopes when sequentially mixed with the soluble gp140 kind as immunogens in a prime-boost mode. We first confirmed that gp140 DNA prime-gp145 Tiantan vaccinia (TV) enhance probably represents a common format for inducing potent nAb response in mice.
However, when examined in rhesus macaque, this modality confirmed little effectiveness. To enhance the efficacy, we prolonged the unique modality by including a robust protein enhance, particularly native-like SOSIP.664 trimer displayed on ferritin-based nanoparticle (NP), which was generated by a newly developed click on method. The ensuing three-immunization routine succeeded in eliciting tier-2 nAb response with substantial breadth when carried out in rhesus macaque over a brief 8-week schedule. Importantly, the elicited nAb response was in a position to successfully comprise viremia upon a heterologous SHIV problem. Collectively, our research highlighted that diversification of Env immunogens, in each varieties and formulations, underneath the framework of a sequential immunization scheme would possibly open new alternative towards HIV vaccine growth.
An efficacious HIV-1 vaccine has remained an elusive goal for nearly 40 years. The sheer variety of the virus is one of the most important roadblocks for vaccine growth. HIV-1 often mutates and numerous strains predominate in numerous geographic areas, making the event of a globally relevant vaccine extraordinarily troublesome. Multiple approaches have been taken to overcome the problem of viral variety, together with sequence optimization, growth of consensus and mosaic sequences and the use of totally different prime-boost approaches. To develop an efficacious vaccine, these approaches may have to be mixed. One method to probably synergize these approaches is to use a rationally designed protein nanoparticle that enables for the native-like presentation of antigens, such because the self-assembling protein nanoparticle.
Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates
The seek for a preventive vaccine towards HIV an infection stays an ongoing problem, indicating the necessity for novel approaches. Parainfluenza virus 5 (PIV5) is a paramyxovirus replicating within the higher airways that isn’t related with any animal or human pathology. In animal fashions, PIV5-vectored vaccines have proven safety towards influenza, RSV, and different human pathogens. Here, we generated PIV5 vaccines expressing HIV envelope (Env) and SIV Gag and administered them intranasally to macaques, adopted by boosting with virus-like particles (VLPs) containing trimeric HIV Env. Moreover, we in contrast the immune responses generated by PIV5-SHIV prime/VLPs enhance routine in naïve vs a management group wherein pre-existing immunity to the PIV5 vector was established.
We display for the primary time that intranasal administration of PIV5-based HIV vaccines is protected, well-tolerated and immunogenic, and that boosting with adjuvanted trimeric Env VLPs enhances humoral and mobile immune responses. The PIV5 prime/VLPs enhance routine induced strong and sturdy systemic and mucosal Env-specific antibody titers with practical actions together with ADCC and neutralization. This routine additionally induced extremely polyfunctional antigen-specific T cell responses. Importantly, we present that diminished responses due to PIV5 pre-existing immunity may be overcome partly with VLP protein boosts.
Overall, these outcomes set up that PIV5-based HIV vaccine candidates are promising and warrant additional investigation together with transferring on to primate problem research. This blended strategies research aimed to consider the feasibility and preliminary efficacy of a totally automated, interactive smartphone-delivered intervention for smoking cessation amongst individuals dwelling with HIV in Cambodia. We used the explanatory sequential design, with a pilot two-group single-blind randomized managed trial (N = 50) adopted by in-depth interviews with all trial individuals. In the trial, individuals had been randomized to Standard Care (SC) or Automated Messaging (AM) group. SC comprised temporary recommendation to give up and self-help supplies.

Exploring HIV stigma amongst future healthcare suppliers in Indonesia
Future healthcare professionals are an vital group for interventions to get rid of HIV stigma within the well being workforce. Researchers examined HIV stigma and its relationship with healthcare self-discipline, HIV information, and religiosity amongst nursing, medical, and midwifery college students (N = 505) in three areas of Indonesia. In a multivariable linear mannequin, larger HIV stigma was related with male intercourse, decrease ranges of earnings and HIV information, and better ranges of religiosity. An interplay of healthcare self-discipline and province was additionally important. Medical college students in Jakarta had larger predicted stigma scores in contrast to nursing college students in Jakarta and in contrast to medical college students in different provinces.
Nursing college students in Papua had decrease predicted stigma scores in contrast to medical and midwifery college students in Papua and in contrast to nursing college students elsewhere. Strategies to cut back HIV stigma within the Indonesian well being workforce ought to embrace a robust deal with pre-clinical academic settings and contemplate public nursing establishments as offering attainable greatest apply fashions. Human immunodeficiency virus sort 1 (HIV-1) is principally transmitted by sexual activity, and efficient microbicides stopping HIV-1 transmission are nonetheless required.
Recombinant HIV-1 Envelope, His Tag |
7-07590 |
CHI Scientific |
1000µg |
Ask for price |
HIV 1 envelope recombinant antigen |
00176-V-01mg |
Virogen |
0,1 mg |
EUR 267.5 |
|
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
HIV 1 envelope recombinant antigen |
00176-V-1000ug |
Virogen |
1000 ug |
EUR 1282.5 |
|
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
Recombinant HIV-1 Envelope (233) |
7-07585 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 Envelope (233) |
7-07586 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 Envelope (233) |
7-07587 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant HIV-2 Envelope |
7-07746 |
CHI Scientific |
1000µg |
Ask for price |
HIV 1, 2 envelope recombinant antigen |
00175-V-01mg |
Virogen |
0,1 mg |
EUR 267.5 |
|
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV 1, 2 envelope recombinant antigen |
00175-V-1000ug |
Virogen |
1000 ug |
EUR 1282.5 |
|
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
Recombinant HIV-1 p24 His Tag |
7-07606 |
CHI Scientific |
5µg |
Ask for price |
Recombinant HIV-1 p24 His Tag |
7-07607 |
CHI Scientific |
20µg |
Ask for price |
Recombinant HIV-1 p24 His Tag |
7-07608 |
CHI Scientific |
1mg |
Ask for price |
Recombinant HIV-1 gp41, His tag |
7-07627 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 gp41, His tag |
7-07628 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 gp41, His tag |
7-07629 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant HIV-1 Envelope conjugated to HIV-2 gp39 |
7-07711 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 Envelope conjugated to HIV-2 gp39 |
7-07712 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 Envelope conjugated to HIV-2 gp39 |
7-07713 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant HIV Type-O Envelope |
7-07714 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV Type-O Envelope |
7-07715 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV Type-O Envelope |
7-07716 |
CHI Scientific |
1000µg |
Ask for price |
HIV 1 Envelope gp41 Protein |
abx060584-05mg |
Abbexa |
0.5 mg |
EUR 940 |
|
HIV 1 Envelope gp41 Protein |
abx060585-100ug |
Abbexa |
100 ug |
EUR 1080 |
|
HIV-1 Envelope (233) Protein |
20-abx260140 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1372.00
|
|
|
Recombinant HIV-1 gp 41 Envelope Protein |
VAng-0532Lsx-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: HIV type 1 Glycoprotein 41 Envelope Antigen, recombinant protein from E. coli, MW 146 kDa with Beta-galactosidase (114 kDa), 1.00 mg/mL. |
Recombinant HIV-1 p24 gag, His Tag |
7-07609 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 p24 gag, His Tag |
7-07610 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 p24 gag, His Tag |
7-07611 |
CHI Scientific |
1000µg |
Ask for price |
HIV-1 gp41, His tag |
E410A25-10 |
EnoGene |
10μg |
EUR 694 |
HIV-1 p24, His tag |
E410A26-20 |
EnoGene |
20μg |
EUR 434 |
Recombinant (E.Coli) HIV-1 Envelope conjugated to HIV-2 gp39 |
RP-564 |
Alpha Diagnostics |
100 ug |
EUR 286 |
Recombinant HIV-2 gp36, His Tag |
7-07738 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-2 gp36, His Tag |
7-07739 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-2 gp36, His Tag |
7-07740 |
CHI Scientific |
1000µg |
Ask for price |
HIV 2 Envelope Protein |
abx060590-1mg |
Abbexa |
1 mg |
EUR 1574 |
|
HIV-2 Envelope Protein |
20-abx260147 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1372.00
|
|
|
Recombinant HIV-1 Envelope Protein, Untagged, E.coli-100ug |
QP12241-100ug |
EnQuireBio |
100ug |
EUR 218 |
Recombinant HIV-1 Envelope Protein, Untagged, E.coli-1mg |
QP12241-1mg |
EnQuireBio |
1mg |
EUR 1061 |
Recombinant HIV-1 Envelope Protein, Untagged, E.coli-500ug |
QP12241-500ug |
EnQuireBio |
500ug |
EUR 663 |
Recombinant (E.Coli, His-tag) HIV-1 pol Integrase |
RP-555 |
Alpha Diagnostics |
10 ug |
EUR 164 |
Recombinant (E.Coli, His-tag)HIV-1 p31 Integrase |
RP-579 |
Alpha Diagnostics |
2 ug |
EUR 164 |
Recombinant HIV-1 gp41, MBP tag |
7-07630 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 gp41, MBP tag |
7-07631 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 gp41, MBP tag |
7-07632 |
CHI Scientific |
1000µg |
Ask for price |
HIV-1 Envelope conjugated to HIV-2 gp39 Protein |
20-abx260144 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1372.00
|
|
|
Recombinant Zika Envelope Protein, His, E.coli-100ug |
QP13997-HIS-100ug |
EnQuireBio |
100ug |
EUR 218 |
Recombinant Zika Envelope Protein, His, E.coli-10ug |
QP13997-HIS-10ug |
EnQuireBio |
10ug |
EUR 201 |
Recombinant Zika Envelope Protein, His, E.coli-1mg |
QP13997-HIS-1mg |
EnQuireBio |
1mg |
EUR 1261 |
Recombinant Zika Envelope Protein, His, E.coli-2ug |
QP13997-HIS-2ug |
EnQuireBio |
2ug |
EUR 155 |
Recombinant Zika Envelope Protein, His, E.coli-500ug |
QP13997-HIS-500ug |
EnQuireBio |
500ug |
EUR 663 |
Recombinant Zika Envelope Protein, His, E.coli-50ug |
QP13997-HIS-50ug |
EnQuireBio |
50ug |
EUR 545 |
Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-100ug |
QP12353-100ug |
EnQuireBio |
100ug |
EUR 218 |
Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-1mg |
QP12353-1mg |
EnQuireBio |
1mg |
EUR 1061 |
Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-500ug |
QP12353-500ug |
EnQuireBio |
500ug |
EUR 663 |
Recombinant (E.Coli, His-tag) HIV-1 gp120 nef Mosaic |
RP-534 |
Alpha Diagnostics |
100 ug |
EUR 286 |
HIV type O envelope antigen |
00178-V-01mg |
Virogen |
0,1 mg |
EUR 267.5 |
|
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
HIV type O envelope antigen |
00178-V-1000ug |
Virogen |
1000 ug |
EUR 1282.5 |
|
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
HIV 2 gp36 envelope antigen |
00180-V-01mg |
Virogen |
0,1 mg |
EUR 267.5 |
|
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
HIV 2 gp36 envelope antigen |
00180-V-1000ug |
Virogen |
1000 ug |
EUR 1282.5 |
|
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
HIV 2 Envelope gp36 Protein |
abx060591-1mg |
Abbexa |
1 mg |
EUR 1358 |
|
HIV 2 Envelope gp36 Protein |
abx060592-100ug |
Abbexa |
100 ug |
EUR 1066 |
|
HIV Type-O Envelope Protein |
20-abx260145 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1372.00
|
|
|
Recombinant HIV-2 gp36 Protein, His, E.coli-100ug |
QP12269-HIS-100ug |
EnQuireBio |
100ug |
EUR 201 |
Recombinant HIV-2 gp36 Protein, His, E.coli-1mg |
QP12269-HIS-1mg |
EnQuireBio |
1mg |
EUR 663 |
Recombinant HIV-2 gp36 Protein, His, E.coli-500ug |
QP12269-HIS-500ug |
EnQuireBio |
500ug |
EUR 463 |
Recombinant HIV-2 Envelope Protein, Untagged, E.coli-100ug |
QP12267-100ug |
EnQuireBio |
100ug |
EUR 218 |
Recombinant HIV-2 Envelope Protein, Untagged, E.coli-1mg |
QP12267-1mg |
EnQuireBio |
1mg |
EUR 1061 |
Recombinant HIV-2 Envelope Protein, Untagged, E.coli-500ug |
QP12267-500ug |
EnQuireBio |
500ug |
EUR 663 |
HCC-1 (CCL14) Human Recombinant Protein, His Tag |
PROTQ16627-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
Description: HCC-1 Human Recombinant fused with a 21 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 95 amino acids (20-93 a.a.) and having a molecular mass of 10.9kDa. The HCC-1 is purified by proprietary chromatographic techniques. |
Recombinant HIV-2 gp36, MBP tag |
7-07735 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-2 gp36, MBP tag |
7-07736 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-2 gp36, MBP tag |
7-07737 |
CHI Scientific |
1000µg |
Ask for price |
Envelope-1, Dengue Virus Subtype 1 Recombinant Protein, Insect Cells |
PROTB1PNJ5-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
Description: Recombinant Dengue Virus Subtype 1 produced in Insect Cells is a polypeptide chain containing amino acids 281-675 and having a molecular weight of approximately 50kDa. ;Dengue Envelope-1 is purified by proprietary chromatographic technique. |
Human, LAG-1 (CCL4L1) Human Recombinant Protein, His Tag |
PROTQ8NHW4-1 |
BosterBio |
Regular: 20ug |
EUR 317 |
Description: LAG-1 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 94 amino acids (24-92 a.a.) and having a molecular mass of 10.5kDa (Molecular weight on SDS-PAGE will appear higher).;LAG-1 is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
NRN1 Human, Neuritin-1 Human Recombinant Protein, His Tag |
PROTQ9NPD7-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
Description: Neuritin-1 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain (Ala28-Gly116) containing 99 amino acids including a 10 aa His tag at N-terminus. The total calculated molecular mass is 11.02kDa. |
KLK1 Human, Kallikrein-1 Human Recombinant Protein, His Tag |
PROTP06870-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
Description: Kallikrein-1 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 259 amino acids (25-262) and having a molecular mass of 28.7kDa.;KLK1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-100ug |
QP12237-100ug |
EnQuireBio |
100ug |
EUR 218 |
Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-1mg |
QP12237-1mg |
EnQuireBio |
1mg |
EUR 1061 |
Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-500ug |
QP12237-500ug |
EnQuireBio |
500ug |
EUR 663 |
Visfatin Recombinant Protein Human, His Tag |
PROTP43490-1 |
BosterBio |
Regular: 25ug |
EUR 317 |
Description: Visfatin Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 511 amino acids and having a molecular mass of 57 kDa. ;The recombinant human Visfatin is fused to His tag at N-Terminus. |
TXN1, Thioredoxin Recombinant Protein, His Tag |
PROTP0AA25-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
Description: Recombinant Thioredoxin produced in E.Coli is a single, non-glycosylated polypeptide chain containing 119 amino acids (2-109 a.a.) and having a molecular mass of 12.9kDa. TRX contains an amino acid His Tag N-terminus and is purified by proprietary chromatographic techniques. |
Streptavidin, Streptavidin Recombinant Protein, His Tag |
PROTP22629-1 |
BosterBio |
Regular: 20ug |
EUR 317 |
Description: Recombinant Streptomyces Avidinii Streptavidin produced in E.Coli is a single, non-glycosylated polypeptide chain (25-183) containing a total of 167 amino acids and having a molecular mass of 17kDa. The Streptavidin protein is fused to an 8 aa N-terminal His-Tag and purified by proprietary chromatographic techniques. |
C5a (His-Tag), murine recombinant protein |
P1112-.1 |
ApexBio |
100 µg |
EUR 962 |
Description: Mouse complement C5a is a 77-amino acid peptide and is generated during complement activation from the ?-chain of complement C5. Its molecular mass is 9 kDa. Mouse C5a shares 60% and 82% amino acid sequence identity to human C5a and rat C5a, respectively |
C5a (His-Tag), murine recombinant protein |
P1112-1 |
ApexBio |
1 mg |
EUR 6940 |
Description: Mouse complement C5a is a 77-amino acid peptide and is generated during complement activation from the ?-chain of complement C5. Its molecular mass is 9 kDa. Mouse C5a shares 60% and 82% amino acid sequence identity to human C5a and rat C5a, respectively |
HIV-1 Tat Protein Peptide |
B1433-1 |
ApexBio |
1 mg |
EUR 128 |
Description: HIV-1 Tat Protein Peptide |
IL-1-alpha Interleukin-1 alpha Mouse Recombinant Protein, His Tag |
PROTP01582-1 |
BosterBio |
Regular: 20ug |
EUR 317 |
Description: IL 1 alpha Mouse Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 179 amino acids (115-270 a.a) and having a molecular mass of 20.4kDa.;IL 1 alpha is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
IL-1-alpha Interleukin-1 alpha Human Recombinant Protein, His Tag |
PROTP01583-1 |
BosterBio |
Regular: 20ug |
EUR 317 |
Description: IL-1A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 159 amino acids fragment (113-271) with an amino-terminal hexahistidine tag and having a total molecular mass of 22.5kDa. ;The Interleukin-1 alpha His-tag is purified by proprietary chromatographic techniques. |
IL-1-beta Interleukin-1 beta Mouse Recombinant Protein, His Tag |
PROTP10749-1 |
BosterBio |
Regular: 25ug |
EUR 317 |
Description: Interleukin-1 beta Mouse Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 189 amino acids and having a molecular mass of 21 kDa. ;The IL-1b is fused to His-Tag and purified by proprietary chromatographic techniques. |
IL-1-alpha Interleukin-1 alpha Rat Recombinant Protein, His Tag |
PROTP16598-1 |
BosterBio |
Regular: 20ug |
EUR 317 |
Description: IL 1 alpha Rat Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 179 amino acids (115-270 a.a) and having a molecular mass of 20.2kDa. |
Recombinant HIV Type-O gp41, MBP tag |
7-07720 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV Type-O gp41, MBP tag |
7-07721 |
CHI Scientific |
500µg |
Ask for price |
Amphibian pores and skin is a wealthy supply of protection peptides with antiviral exercise. Here, we characterised a lectin-like peptide, fejerlectin (RLCYMVLPCP), remoted from the pores and skin of the frog Fejervarya limnocharis. Fejerlectin confirmed important hemagglutination and d-(+)-galacturonic acid-binding actions. Furthermore, fejerlectin suppressed the early entry of HIV-1 into goal cells by binding to the N-terminal heptad repeat of HIV-1 gp41 and stopping 6-HB formation and Env-mediated membrane fusion. Fejerlectin is the smallest lectin-like peptide recognized to date and represents a new and promising platform for anti-HIV-1 drug growth.